High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists

European Journal of Pharmacology

Volumn 427, Issue 3, 2001, Pages 285-293

  Wang, Pei Ran ^a   Guo, Qiu ^a   Ippolito, Marc ^a   Wu, Margaret ^a   Milot, Denise ^a   Ventre, John ^a   Doebber, Tom ^a   Wright, Samuel D ^a   Chao, Yu Sheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Animal model; Diabetic dyslipidemia; Fenofibrate; Insulin sensitivity

Indexed keywords

3 HYDROXYBUTYRIC ACID; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA SELECTIVE AGONIST; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DYSLIPIDEMIA; ENZYME ACTIVITY; FAT INTAKE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HAMSTER; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; INSULIN; LIPIDS; LIVER; MALE; MESOCRICETUS; OXIDATION-REDUCTION; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 0035929192     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01249-3     Document Type: Article

References (42)

1. Regulation of gallbladder cholesterol concentration in the hamster. Role of hepatic cholesterol level
2. Fenofibrate: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia
3. Review of European clinical experience with fenofibrate
4. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
5. Fenofibrate and rosiglitazone lower serum triglyceride with opposing effects on body weight
6. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Disease Cardiovascular Disease Prevention (SENDCAP) Study
7. Demonstration of a critical role of free fatty acids in mediating counter-regulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans
8. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus
9. Bezafibrate and simvastatin combination therapy for diabetic dyslipidemia: Efficacy and safety
10. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidemia
11. Role of muscle in triglyceride metabolism
12. Triglyceride as a risk factor for coronary artery disease
13. PPARa activators improve insulin sensitivity and reduce adiposity
14. Insulin resistance and lipid metabolism
15. Effects if comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X
16. Reduced beta-cell contributes to impaired glucose tolerance in dogs made obese by high-fat feeding
17. Structure and biochemical effects of fenofibrate
18. The db/db mouse, a model for diabetic dyslipidemia: Molecular characterization and effects of Western diet feeding
19. Lack of predictability of classical animal model for hypolipidemic activity: A good time for mice?
20. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance
21. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complimentary mechanism relative to fibrates
22. Mitochondria and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats
23. Observation on the affinity for carnitine, and malonyl-CoA sensitivity of carnitine palmitoyl transferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat
24. Effects of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidemia
25. Enhanced skeletal muscle insulin sensitivity in year-old rats adapted to hypergravity
26. Effects of gemfibrozil on insulin sensitivity and one hameostatic variables in hypertriglyceridemic patients
27. Effects of dietary cholesterol and fatty acids on plasma cholesterol and hepatic lipoprotein metabolism
28. Overview of fenofibrate
29. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes
30. Aspect of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate
31. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin
32. Time course of insulin resistance associated with feeding dogs a high-fat diet
33. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia
34. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
35. The effects of different dietary fats and cholesterol on serum lipoprotein concentration in hamster
36. A comparison of the effects of selective increase in peripheral or portal insulin on hepatic glucose production in the conscious dog
37. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog
38. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster
39. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia
40. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor anti-lipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients
41. Fibrates, dyslipidemia and cardiovascular disease
42. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidemic syndrome